EP1471942A1 - Lyophilisierte zubereitung enthaltend immuncytokine - Google Patents

Lyophilisierte zubereitung enthaltend immuncytokine

Info

Publication number
EP1471942A1
EP1471942A1 EP03737257A EP03737257A EP1471942A1 EP 1471942 A1 EP1471942 A1 EP 1471942A1 EP 03737257 A EP03737257 A EP 03737257A EP 03737257 A EP03737257 A EP 03737257A EP 1471942 A1 EP1471942 A1 EP 1471942A1
Authority
EP
European Patent Office
Prior art keywords
pharmaceutical preparation
preparation according
solution
immunocytokine
lyophilized pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03737257A
Other languages
German (de)
English (en)
French (fr)
Inventor
Hans-Peter Zobel
Sven Oliver Arndt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of EP1471942A1 publication Critical patent/EP1471942A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
EP03737257A 2002-02-06 2003-01-14 Lyophilisierte zubereitung enthaltend immuncytokine Withdrawn EP1471942A1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10204792A DE10204792A1 (de) 2002-02-06 2002-02-06 Lyophilisierte Zubereitung enthaltend Immuncytokine
DE10204792 2002-02-06
PCT/EP2003/000259 WO2003066102A1 (de) 2002-02-06 2003-01-14 Lyophilisierte zubereitung enthaltend immuncytokine

Publications (1)

Publication Number Publication Date
EP1471942A1 true EP1471942A1 (de) 2004-11-03

Family

ID=27588393

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03737257A Withdrawn EP1471942A1 (de) 2002-02-06 2003-01-14 Lyophilisierte zubereitung enthaltend immuncytokine

Country Status (17)

Country Link
US (1) US20050220758A1 (zh)
EP (1) EP1471942A1 (zh)
JP (1) JP4422485B2 (zh)
KR (1) KR20040091015A (zh)
CN (1) CN1627958A (zh)
AR (1) AR038355A1 (zh)
AU (1) AU2003244470B2 (zh)
BR (1) BR0307448A (zh)
CA (1) CA2475211A1 (zh)
DE (1) DE10204792A1 (zh)
MX (1) MXPA04007562A (zh)
PE (1) PE20030898A1 (zh)
PL (1) PL369754A1 (zh)
RU (1) RU2316348C2 (zh)
TW (1) TW200303756A (zh)
WO (1) WO2003066102A1 (zh)
ZA (1) ZA200407028B (zh)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9770517B2 (en) 2002-03-01 2017-09-26 Immunomedics, Inc. Anti-Trop-2 antibody-drug conjugates and uses thereof
JP2006045162A (ja) * 2004-08-06 2006-02-16 Takeda Chem Ind Ltd 注射用ペプチド含有組成物
PT1778723E (pt) * 2004-08-17 2013-01-25 Regeneron Pharma Formulações de antagonista de il-1
EP1930006A4 (en) * 2005-09-28 2010-10-13 Daiichi Sankyo Co Ltd PROCESS FOR PRODUCING LYOPHILIZED PREPARATION CONTAINING QUINOLONE
CN101822820A (zh) 2005-12-20 2010-09-08 布里斯托尔—迈尔斯斯奎布公司 稳定蛋白质制剂
US9309316B2 (en) 2005-12-20 2016-04-12 Bristol-Myers Squibb Company Stable subcutaneous protein formulations and uses thereof
DE102007050165B4 (de) * 2007-10-19 2010-06-17 Stiftung Tierärztliche Hochschule Hannover Stabilisierte Lösung, Verfahren zu deren Herstellung sowie deren Verwendung und Arzneimittel in Form einer stabilisierten Lösung
ES2525257T3 (es) * 2009-02-25 2014-12-19 Supratek Pharma, Inc. Composiciones de ciclopolisacárido y de bendamustina
TWI527590B (zh) * 2011-06-17 2016-04-01 艾瑞斯貿易公司 Ｆｇｆ－１８之凍乾調配物
US9382329B2 (en) 2012-08-14 2016-07-05 Ibc Pharmaceuticals, Inc. Disease therapy by inducing immune response to Trop-2 expressing cells
WO2015047510A1 (en) * 2013-09-27 2015-04-02 Immunomedics, Inc. Anti-trop-2 antibody-drug conjugates and uses thereof
ES2887079T3 (es) 2014-04-28 2021-12-21 Eisai R&D Man Co Ltd Preparación de HGF liofilizada
US11548926B2 (en) 2016-03-17 2023-01-10 Eisai R&D Management Co., Ltd. Method for producing an active hepatocyte growth factor (HGF)
CN114224853B (zh) * 2022-01-04 2022-09-23 山东新时代药业有限公司 聚乙二醇化重组人粒细胞刺激因子注射用冻干制剂
CN114515334B (zh) * 2022-02-22 2024-02-20 史辛艺 一种脂肪间充质干细胞因子冻干粉及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0150067A3 (en) * 1984-01-23 1986-12-30 Takeda Chemical Industries, Ltd. Stable composition of gamma-interferon
JPS61197527A (ja) * 1985-02-25 1986-09-01 Takeda Chem Ind Ltd インタ−ロイキン−２組成物
EP0158487B1 (en) * 1984-04-09 1991-08-28 Takeda Chemical Industries, Ltd. Stable composition of interleukin-2
US5104651A (en) * 1988-12-16 1992-04-14 Amgen Inc. Stabilized hydrophobic protein formulations of g-csf
DE4242863A1 (de) * 1992-12-18 1994-06-23 Boehringer Mannheim Gmbh Stabile lyophilisierte pharmazeutische Zubereitungen von G-CSF
JP3822383B2 (ja) * 1993-12-17 2006-09-20 持田製薬株式会社 可溶性トロンボモジュリン含有組成物
EP0689843B1 (en) * 1993-12-17 2003-09-10 Mochida Pharmaceutical Co., Ltd. Composition containing soluble thrombomodulins
US5580856A (en) * 1994-07-15 1996-12-03 Prestrelski; Steven J. Formulation of a reconstituted protein, and method and kit for the production thereof
US5770700A (en) * 1996-01-25 1998-06-23 Genetics Institute, Inc. Liquid factor IX formulations
EP0852951A1 (de) * 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO03066102A1 *

Also Published As

Publication number Publication date
MXPA04007562A (es) 2004-11-10
ZA200407028B (en) 2006-02-22
CN1627958A (zh) 2005-06-15
US20050220758A1 (en) 2005-10-06
AU2003244470A1 (en) 2003-09-02
AR038355A1 (es) 2005-01-12
PE20030898A1 (es) 2003-10-25
KR20040091015A (ko) 2004-10-27
RU2316348C2 (ru) 2008-02-10
TW200303756A (en) 2003-09-16
PL369754A1 (en) 2005-05-02
DE10204792A1 (de) 2003-08-14
RU2004126942A (ru) 2005-06-10
AU2003244470B2 (en) 2008-03-13
JP2005516998A (ja) 2005-06-09
CA2475211A1 (en) 2003-08-14
JP4422485B2 (ja) 2010-02-24
WO2003066102A1 (de) 2003-08-14
BR0307448A (pt) 2004-12-28

Similar Documents

Publication Publication Date Title
EP0941121B1 (de) Stabile lyophilisierte pharmazeutische zubereitungen von mono- oder polykonalen antikörpern
EP1687031B1 (de) Pharmazeutische zubereitung enthaltend einen antikörper gegen den rezeptor für einen epidermalen wachstumsfaktor (egf-rezeptor)
EP0674524B1 (de) Stabile lyophilisierte pharmazeutische zubereitungen von g-csf
EP0674525B1 (de) Lagerstabile wässrige pharmazeutische zubereitungen von g-csf
EP1648485B2 (de) Formulierung für proteinarzneimittel ohne zusatz von humanem serumalbumin (hsa)
WO2003066102A1 (de) Lyophilisierte zubereitung enthaltend immuncytokine
DE69532970T3 (de) Sprühgetrocknetes erythropoietin
EP1455824A2 (de) Lyophilisierte zubereitung enthaltend antikörper gegen den egf-rezeptor
DE69532884T2 (de) Verfahren und mittel zur verabreichung von insulin über die lunge
DE3520228A1 (de) Wasserloesliche bioaktive trockenfeststoffzusammensetzung, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische praeparate
DD298053A5 (de) Verfahren zum herstellen einer stabilen zubereitung eines pharmazeutischen peptides
DE2751717A1 (de) Neue verbesserte gammaglobuline fuer intravenoese injektion und verfahren zu ihrer herstellung
EP0529300B1 (de) Neues rekombinantes Human-IFN-beta, Verfahren zu dessen Herstellung und dieses enthaltende pharmazeutische Zubereitungen
EP1339403A2 (de) Repinotan-kit
EP1406658A1 (de) Flüssige formulierung enthaltend cetuximab und einen polyoxyethylensorbitan-fettsäureester
WO1998047490A1 (de) Stabile pharmazeutische darreichungsform für peptide, proteine und nukleinsäuren
EP0420049B1 (de) Stabilisierte Leukocyten-Interferone
AT395017B (de) Verfahren zur herstellung eines neuen lymphokins (lk 2) sowie verwendung von lk 2 zur herstellung eines pharmazeutischen praeparates
EP0869811B1 (de) Immunologisch wirksame mistelextraktzubereitungen
EP2293817B1 (de) Stabilisierte flüssigformulierung

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040628

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO

17Q First examination report despatched

Effective date: 20070413

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20100526